Membrane adsorption in vancomycin treatment is membrane type dependent in CVVHDF: dose correction is crucial

Honoré, Patrick M.; Redant, Sébastien; Djimafo, Pharan; Préseau, Thierry; Cismas, Bogdan Vasile; Kaefer, Keitiane; Gutierrez, Leonel Barreto; Anane, Sami; Attou, Rachid; Gallerani, Andrea; Bels, David De

doi:10.1186/s13054-022-03991-5

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As vancomycin remains a first choice antibiotic to treat suspected methicillin-resistant Staphylococcus aureus infections in critically ill patients, we considered it relevant to assess vancomycin sequestration in a new polyacrylonitrile filter used presently. As a matter of fact, in early 2022, Honore et al suggested clinicians should be aware of the specific adsorptive properties of the membrane used during continuous renal replacement therapy (CRRT) and of the need for vancomycin monitoring [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Vancomycin Sequestration in ST Filters: An In Vitro Study

Baud

Houzé²,

Raphalen³

et al. 2023

Antibiotics

View full text Add to dashboard Cite

Background. Sequestration of vancomycin in ST® filters used in continuous renal therapy is a pending question. Direct vancomycin-ST® interaction was assessed using the in vitro NeckEpur® technology. Method. ST150® filter and Prismaflex dialyzer, Baxter-Gambro, were used. Two modes were assessed in duplicate: (i) continuous diafiltration (CDF): 4 L/h, (ii) continuous dialysis (CD): 2.5 L/h post-filtration. Results. The mean initial vancomycin concentration in the central compartment (CC) was 51.4 +/− 5.0 mg/L. The mean percentage eliminated from the CC over 6 h was 91 +/− 4%. The mean clearances from the CC by CDF and CD were 2.8 and 1.9 L/h, respectively. The mean clearances assessed using cumulative effluents were 4.4 and 2.2 L/h, respectively. The mean percentages of the initial dose eliminated in the effluents from the CC by CDF and CD were 114 and 108% with no detectable sequestration of vancomycin in both modes of elimination. Discussion. Significant sequestration adds a clearance to that provided by CDF and CD. The study provides multiple evidence from the CC, the filter, and the effluents of the lack of an increase in total clearance in comparison with the flow rates without significant sequestration in the ST® filter comparing cumulative effluents to the initial dose in the CC. Conclusions. There is no evidence ST® filters directly sequestrate vancomycin.

show abstract

Section: Introductionmentioning

confidence: 99%

Vancomycin Sequestration in ST Filters: An In Vitro Study

Baud

Houzé²,

Raphalen³

et al. 2023

Antibiotics

View full text Add to dashboard Cite

show abstract

Effect of Continuous Renal Replacement Therapy with the oXiris Hemofilter on Critically Ill Patients: A Narrative Review

Sun

Chang

et al. 2022

JCM

View full text Add to dashboard Cite

Critically ill patients with sepsis and severe COVID-19 are commonly characterized by a dysregulated immune response and an acute kidney injury. Continuous renal replacement therapy (CRRT) is now proposed as a promising adjuvant therapy to treat these critically ill patients by removing cytokines, pathogen-associated molecular patterns, and damage-associated molecular patterns from the blood. Although multiple hemofilters, including high-cutoff membranes, the oXiris hemofilter, the CytoSorb hemoadsorption device, and the Toraymyxin hemoperfusion cartridge, have been used in current clinical practice, the use of the oXiris hemofilter in critically ill patients is of particular interest because it is the only kind of hemofilter that can provide renal replacement therapy, remove endotoxins, and adsorb cytokines simultaneously. During the past five years, a growing body of literature has shown that CRRT with the oXiris hemofilter can improve hemodynamics and organ function and can decrease cytokines and endotoxins in both septic and COVID-19 patients. Here, we performed a narrative review to describe the development history of the oXiris hemofilter and to discuss the therapeutic effect of oXiris-CRRT on critically ill patients by searching the PubMed, Web of Science, and clinicaltrials.gov databases for articles published from inception to 8 September 2022 (updated on 1 November) with an English language restriction. We also summarized the current knowledge on anticoagulation techniques and safety concerns when delivering oXiris-CRRT sessions.

show abstract

Membrane adsorption in vancomycin treatment is membrane type dependent in CVVHDF: dose correction is crucial

Cited by 2 publications

References 5 publications

Vancomycin Sequestration in ST Filters: An In Vitro Study

Vancomycin Sequestration in ST Filters: An In Vitro Study

Effect of Continuous Renal Replacement Therapy with the oXiris Hemofilter on Critically Ill Patients: A Narrative Review

Contact Info

Product

Resources

About